[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,46,76,111,140,169,199,226,251,275,308,336,362],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100613359","two-post-operative-pain-protocols-at-discharge-for-orthopaedic-patients-100613359",false,"NCT07265557","Two Post-Operative Pain Protocols at Discharge for Orthopaedic Patients","A Pilot Randomized Controlled Trial Comparing Two Post-Operative Pain Protocols at Discharge for Orthopaedic Patients: A Pilot Study","Inclusion Criteria:\n\n1. Patients 18 years of age or older\n2. Underwent a major operative orthopaedic procedure\n\nExclusion Criteria:\n\n1. Contraindication for NSAIDs.\n2. Preoperative chronic opioid use (preoperative use of \\>14 days and average of \\>30 Morphine Milligram Equivalents per day).\n3. Active treatment for opioid use disorder.\n4. Previous or current illicit drug use.\n5. Major surgery for pathologic (cancer-related) condition.\n6. Hand surgery.\n7. Concurrent operative treatment by another specialty team.\n8. Discharged to an extended medical care facility.\n9. Incarceration.\n10. Women who are pregnant or planning to become pregnant in the next 6 weeks.\n11. Expected injury survival of less than 6 weeks.\n12. Terminal illness with expected survival of less than 6 weeks.\n13. Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.\n14. Currently enrolled in a trial that does not permit co-enrollment.\n15. Prior enrollment in the trial.\n16. Unable to obtain informed consent.\n17. Non-English speaking\n18. Eligible patient was not approached prior to hospital discharge (missed participant).\n19. Did not provide informed consent (declined participation).\n20. Other reason to exclude the patient, as approved by the Principal Investigator","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a single-center, pilot randomized controlled trial designed to evaluate the feasibility of a definitive trial comparing opioid-free discharge prescriptions to usual care (which includes opioids) in patients undergoing major orthopaedic surgery. The main objective is to inform the design and feasibility of the definitive RCT.",[26,27,28,29],"Orthopaedic Related Pain (Musculoskeletal Pain)","Opioid","Pain","Pilot Study",[27,31,32],"Pilot study","Musculoskeletal Pain","RECRUITING","2026-06-23",{"date":36,"type":37},"2026-06-25","ACTUAL",{"date":39,"type":37},"2025-10-06",{"date":41,"type":20},"2026-12-31",{"name":43,"class":44},"Massachusetts General Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100597815","evaluation-of-virtual-reality-for-reducing-opioid-use-after-cardiac-and-thoracic-surgery-100597815","NCT07063394","Evaluation of Virtual Reality for Reducing Opioid Use After Cardiac and Thoracic Surgery","Evaluation of the Efficacy of Virtual Reality as a Therapeutic Method to Reduce Opioid Consumption in Postoperative Cardiac and Thoracic Surgery","VR-USP","Inclusion Criteria:\n\n* Patients undergoing elective cardiac or thoracic surgeries at the Heart Institute (InCor) of the Hospital das Clínicas of the University of São Paulo.\n* Eligible thoracic surgeries include: pulmonary decortication, thoracic sympathectomy, video-assisted thoracoscopic surgery (VATS), pulmonary biopsy, and pectus excavatum repair using the Nuss procedure.\n* Patients aged between 16 and 40 years.\n* Preserved cognitive function, indicated by a Mini-Mental State Examination (MMSE) score of ≥ 25.\n\nExclusion Criteria:\n\n* Visual impairments.\n* Cognitive impairment (MMSE ≤ 24).\n* Severe upper limb motor limitations.\n* Claustrophobia.\n* Spatial disorientation.\n* Motion sickness or vestibular disorders.\n* Infectious or contagious diseases.","16 Years","40 Years",{"count":57,"type":20},60,[23],"This clinical trial aims to evaluate the efficacy of virtual reality (VR) as an adjunctive therapeutic method to reduce opioid consumption during the postoperative period of cardiac and thoracic surgeries. Conducted at InCor\u002FHCFMUSP, this single-center, prospective, randomized trial will include 60 patients aged 16 to 40 undergoing procedures such as valve replacements, pulmonary decortication, and video-assisted thoracic surgeries.\n\nPatients will be randomized into three groups. The Interactive VR group receives standard anesthesia protocol combined with interactive VR therapy using games and immersive environments. The Passive VR group receives standard protocol combined with passive 360-degree immersive videos. The Control group receives standard anesthesia protocol without VR intervention. The intervention occurs in three daily sessions lasting 30-45 minutes each over the first five postoperative days or until hospital discharge.\n\nThe primary objective is to measure the reduction in total opioid consumption through medical prescriptions and patient-controlled analgesia (PCA) pump usage. Secondary objectives include pain intensity assessed by the Visual Analogue Scale (VAS), incidence of postoperative nausea and vomiting (PONV), duration of mechanical and non-invasive ventilation, length of stay in the ICU and hospital, occurrence of paralytic ileus, patient satisfaction, and cognitive status using the Mini-Mental State Examination (MMSE).\n\nOpioids are standard for postoperative pain but are associated with adverse effects like respiratory depression. VR offers an innovative approach by creating immersive environments that serve as cognitive distractions to modulate pain perception and reduce anxiety. The study anticipates that VR will enhance pain control and improve recovery metrics, serving as a safe and scalable complement to traditional postoperative management.",[61,62,27,63,28],"Heart Surgery","Thoracic Surgery","Virtual Reality",[65,62,27,63,28],"Heart surgery","2026-04-10",{"date":68,"type":37},"2026-04-15",{"date":70,"type":37},"2024-12-10",{"date":72,"type":20},"2027-12-30",{"name":74,"class":75},"Filomena R B G Galas","OTHER_GOV",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100581299","medsmat-mobile-ed-100581299","NCT06848504","MedSMA℞T Mobile ED","Implementing MedSMA℞T Families in the Emergency Department Setting: A Game-based Approach for Improving Opioid Safety Among Adolescents and Parents","Inclusion Criteria:\n\n* Adults who receive an opioid prescription from a study Emergency Department, AND\n* who report having an adolescent, aged 12-18, living at home, AND\n* who speak and understand English\n* Each participant must have the ability to provide informed consent\n\nExclusion Criteria:\n\n* Adults who do not receive an opioid prescription from a study Emergency Department AND\u002FOR\n* who do not have an adolescent, aged 12-18, living at home, AND\u002FOR\n* who do not speak or understand English\n* Adults and\u002For adolescents who do not have the ability to provide informed consent","12 Years",{"count":85,"type":20},244,[23],"The goal of this clinical trial is to learn if a new smartphone-based intervention can help with factors related to opioid misuse in parents and adolescent\u002Fearly adult children. The main question it aims to answer is:\n\n• Can this intervention improve knowledge of, and attitudes towards, opioid misuse over traditional opioid-related counseling alone?\n\nParticipants will, in addition to receiving opioid counseling:\n\n* Join an online meeting with research staff to test the smartphone-based intervention\n* Report demographic information\n* Complete surveys about opioids\n* Complete a family medication safety plan\n* Complete surveys after 3, 6, and 9 months",[89,90,27],"Opiate-Related Disorders","Opiate Use Disorder",[92,93,89,94,27,95,96,97,98,99],"Opioid Education","Opioid Use Disorder","Opiate","Serious Game","Smartphone","Smartphone Game","Medication safety","Adolescent Health","NOT_YET_RECRUITING","2026-03-13",{"date":103,"type":37},"2026-03-17",{"date":105,"type":20},"2026-09",{"date":107,"type":20},"2027-12",{"name":109,"class":44},"Olufunmilola Abraham",3,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":45},"100626427","fentanyl-versus-opioid-free-multimodal-analgesia-for-perioperative-pain-control-in-children-with-mild-to-moderate-obstructive-sleep-apnea-100626427","NCT07435493","Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Children aged 5-10 years.\n* Diagnosed with mild to moderate Obstructive Sleep Apnea (apnea-hypoxia index 1-10).\n* Scheduled for elective adenotonsillectomy.\n* American Society of Anesthesiologists physical status I-II.\n\nExclusion Criteria:\n\n* Severe Obstructive Sleep Apnea (apnea-hypoxia index \\>10).\n* Known allergies to study medications.\n* Patient with predicted difficult air way (Mallampatti 3\\&4).\n* History of opioid use or chronic pain syndromes.\n* Neurological or metabolic disorders affecting pain perception.\n* Parental refusal to consent.","5 Years","10 Years",{"count":120,"type":20},64,[23],"Emphasize that the usage of multimodal analgesia in managing perioperative pain in children with mild to moderate Obstructive Sleep Apnea undergoing adenotonsillectomy may achieve the same efficacy of fentanyl with less respiratory complications and less opioid-related side effects.",[124,125,126,27],"Adenotonsillectomy","Obstructive Sleep Apnea (OSA)","Fentanyl",[128,126,129,130],"opioid","obstructive sleep apnea","adenotonsillectomy","2026-02-23",{"date":133,"type":37},"2026-02-27",{"date":135,"type":20},"2026-11-30",{"date":137,"type":20},"2026-12-30",{"name":139,"class":44},"Ain Shams University",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":157,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":45},"100558744","acute-preoperative-pain-and-chronic-post-surgical-pain-in-emergency-surgery-100558744","NCT06555107","Acute Preoperative Pain and Chronic Post-surgical Pain in Emergency Surgery","POCSE","Inclusion Criteria:\n\n* Age ≥18 years old.\n* Emergency orthopaedic and\u002For abdominal surgery.\n* Informed consent.\n* Affiliation to a social security scheme\n\nExclusion Criteria:\n\n* Intraoperative complications that are life-threatening or require the surgical procedure to be discontinued.\n* Post-operative intensive care unit admission.\n* Ambulatory surgery.\n* Endoscopic surgery.\n* Repeat surgery at the same site in less that 3months.\n* Pregnant or breast-feeding patients.\n* Patients under guardianship or deprived of liberty.\n* Patients suffering from psychiatric pathologies.\n* Patients suffering from neurodegenerative pathologies.\n* Patients for whom self-assessment of pain using a numerical scale (0-10) cannot be carried out (non-communicative patients, non-French-speaking patients, and so on).",{"count":148,"type":20},693,[23],"Studies evaluating postoperative pain as a risk factor for CPSP are almost exclusively carried out in the context of scheduled surgery. As a result, the preoperative pain studied as a risk factor for chronicity is essentially a state of pain that has persisted for several weeks or even several months.\n\nIn emergency surgeries, patients are subject to acute preoperative pain of varying intensity and the duration of which may vary by a few days. A few studies have highlighted the intensity of acute preoperative pain as a factor favouring moderate to severe postoperative pain. At this point, no study has addressed the long-term consequences of this intense preoperative pain the emergency context.\n\nAn evaluation in the field of emergency surgery, where the preoperative pain is often intense and limited in time, would enable us to identify more precisely the impact of acute pain on the incidence of CPSP.\n\nThe investigators are hypothesising that the occurrence of CPSP at 3 months in patients undergoing emergency orthopaedic or abdominal surgery is associated with acute preoperative pain.",[152,153,154,27,155,156],"Chronic Postsurgical Pain","Acute Pain","Emergency Surgery","Postoperative Pain","Risk Factors",[158,152,153,159,128,155],"risk factors","emergency surgery","2026-01-15",{"date":162,"type":37},"2026-01-16",{"date":164,"type":37},"2024-08-29",{"date":166,"type":20},"2027-04",{"name":168,"class":44},"Centre Hospitalier Universitaire, Amiens",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":179,"conditions":180,"keywords":185,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":45},"100618302","opioid-consumption-after-thoracotomy-and-factors-affecting-postoperative-acute-pain-100618302","NCT07329855","Opioid Consumption After Thoracotomy and Factors Affecting Postoperative Acute Pain","Analysis of Opioid Consumption After Thoracotomy and Factors Affecting Postoperative Acute Pain","Inclusion Criteria:\n\n* Patients aged over 18 years\n* Patients scheduled for thoracotomy\n* Patients with an American Society of Anesthesiologists (ASA) physical status classification of I-III\n* Patients who have provided informed consent\n* Patients with a body mass index (BMI) between 18-40 kg\u002Fm²\n\nExclusion Criteria:\n\n* Patients with ASA class IV or higher\n* Patients younger than 18 years old\n* Patients with systemic inflammatory disease\n* Patients receiving continuous anti-inflammatory and\u002For analgesic medication\n* Patients with chronic preoperative pain\n* Pregnant patients\n* Outpatients who received anesthesia outside the operating room\n* Emergency cases\n* Patients who underwent VATS, sternotomy, mediastinoscopy, or tracheal resection\n* Patients with a history of previous thoracic surgery\n* Patients who had a thoracic epidural catheter inserted for postoperative pain management\n* Patients with a BMI \\\u003C18 or \\>40 kg\u002Fm²",{"count":177,"type":20},35,"OBSERVATIONAL","Thoracic surgery operations constitute a significant portion of surgical procedures performed in hospitals. In the United States, more than 50,000 thoracic surgical procedures are performed annually, and more than 80% of these patients experience moderate to severe postoperative pain requiring opioid administration, which increases the risk of complications . It has also been reported that chronic pain develops in approximately 50% of patients after thoracic surgery .\n\nThoracic surgery is commonly associated with severe, multifactorial pain during the postoperative period and is among the surgical branches with a high risk of developing chronic pain Despite advances in understanding postoperative pain mechanisms and improvements in pain management, inadequate postoperative pain control remains an unresolved healthcare problem. Higher acute pain scores are associated with less effective ventilation and coughing, increased incidence of lower respiratory tract infections, and prolonged ICU and hospital stays .\n\nIn the management of acute postoperative pain after thoracic surgery, clinicians have sought alternatives to thoracic epidural analgesia to avoid its potential adverse effects. Truncal blocks such as thoracic paravertebral block, erector spinae plane block, and serratus anterior block have been used to reduce postoperative pain . Additionally, various other analgesic techniques such as patient-controlled analgesia (PCA) and multimodal analgesia have been employed. Historically, the cornerstone of acute postoperative pain control has been systemic opioids administered via oral, intravenous, or thoracic epidural routes . Although opioids provide excellent pain relief, they are associated with significant side effects that can adversely affect recovery .\n\nWith the increasing use of ultrasonography (USG), truncal blocks have become more widespread. Alongside the development of Enhanced Recovery After Thoracic Surgery (ERATS) protocols, efforts have been made to reduce opioid use, leading to differing opinions regarding the management of acute pain after thoracic surgery. To prevent opioid use disorder and potential side effects, opioid-free or opioid-sparing approaches are now being encouraged in perioperative pain management . Conversely, some studies suggest that intraoperative opioid administration may have favorable effects on postoperative acute and chronic pain. Previous research has reported that the average daily opioid consumption after thoracic surgery is approximately 30 morphine milligram equivalents (MME) .\n\nAlthough video-assisted thoracoscopic surgery (VATS) has become more common, thoracotomy cases still constitute a large proportion of thoracic surgery procedures. Moreover, severe postoperative pain after thoracic surgery is most commonly associated with the thoracotomy incision itself. While some studies have suggested that new truncal block techniques may provide effective analgesia and reduce opioid consumption after thoracotomy, further studies are needed to determine which blocks are most commonly preferred and how opioid consumption patterns have changed with the adoption of these newer regional techniques.\n\nA review of the current literature reveals that the factors influencing acute pain after thoracotomy have not been sufficiently evaluated. Therefore, a re-evaluation of the factors affecting acute pain following thoracotomy, considering recent developments in pain management, is necessary. Furthermore, examining the relationship between perioperative opioid consumption, postoperative complications, and hospital length of stay in this patient population will provide valuable contributions to the literature.\n\nThe aim of this study is to evaluate the amount of opioid consumption following thoracotomy and to investigate whether perioperative opioid use affects acute pain, postoperative complications, and the length of hospital stay.",[181,182,27,183,184],"Thoracic Anesthesia","Thoracotomy","Postoperative Pain Management","Length of Hospital Stay",[182,186,187,188,189],"opioid consumption","postoperative acute pain","postoperative complications","length of hospital stay","2026-01-09",{"date":192,"type":37},"2026-01-12",{"date":194,"type":20},"2026-01-05",{"date":196,"type":20},"2026-05-05",{"name":198,"class":75},"Ankara Ataturk Sanatorium Training and Research Hospital",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":45},"100617380","impact-evaluation-of-the-therapeutic-initiatives-prescribing-portrait-and-therapeutics-letter-on-opioid-use-by-dentists-100617380","NCT07317869","Impact Evaluation of the Therapeutic Initiative's Prescribing Portrait and Therapeutics Letter on Opioid Use by Dentists","Impact Evaluation of the Therapeutic Initiative's Prescribing Portrait and Therapeutics Letter on Opioid Use by Dentists for Dental Pain","Inclusion Criteria:\n\nDentists will be eligible to receive an individual prescribing Portrait if they meet all of the following criteria:\n\n* Registered with the British Columbia Medical Services Plan (MSP) as being in active practice;\n* Have a valid mailing address in British Columbia; and\n* Issued ≥10 prescriptions dispensed at community pharmacies between January 5, 2025 and January 5, 2026, as identified in PharmaNet claims data.\n\nPatients will be eligible for inclusion if they meet all of the following criteria:\n\n* Received an opioid prescription from an eligible dentist during the study period (January 6, 2026 to January 6, 2027);\n* The opioid prescription was issued by a dentist; and\n* Were continuously enrolled in the British Columbia Medical Services Plan (MSP) during the 12 months prior to the opioid prescription.\n\nExclusion Criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n* Had a medication dispensed under Plan P in the 12 months prior to the opioid prescription; or\n* Filled a prescription for opioid agonist therapy (OAT) within 180 days prior to the opioid prescription.",{"count":207,"type":20},3498,[23],"The aim of this study is to estimate the impact of providing personalized prescribing data and educational materials on opioid prescribing to dentists in British Columbia, Canada.\n\nThe main research questions are:\n\n1. What is the impact of an intervention on the use of opioids for dental pain? The intervention includes a personalized prescribing report (a \"Portrait\"), brief educational summary, and patient education materials; and\n2. Does the impact of the intervention increase when dentists are also invited to attend facilitated audit-and-feedback group sessions and to develop a practice improvement plan? Using administrative health data, the prescribing of those in different combinations of materials in the Early Group will be compared to those in the Delayed Group to estimate the impact of the materials on prescribing by the dentists.",[211,212,27,213],"Clinical Audit","Quality Improvement","Dentistry",[215,216,217,27],"Randomized controlled trial","Prescribing feedback","Quality improvement",{"date":219,"type":37},"2026-01-08",{"date":221,"type":20},"2026-01-06",{"date":223,"type":20},"2028-01-31",{"name":225,"class":44},"University of British Columbia",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":4},"100607461","study-on-the-relationship-between-opioid-drugs-and-the-therapeutic-efficacy-of-immunotherapy-100607461","NCT07188857","Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy","Inclusion Criteria:\n\n* Aged ≥ 18 years; Histologically confirmed advanced NSCLC (Stage IIIb-IV); Need to receive ICIs treatment; Accompanied by moderate or severe pain (NRS score ≥ 4); Need to use opioid drugs for pain management; Able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* Suffering from severe dysfunction of important organs such as heart, liver, and kidney; Suffering from mental illness or receiving treatment with psychotropic drugs; Pregnant or lactating women; Participating in other clinical trials; Allergic to opioid drugs.","80 Years",{"count":19,"type":20},"Relationship between pain and the efficacy of immunotherapy: Does the degree of pain control affect the therapeutic efficacy of ICIs? Does the use of opioid drugs independently affect the efficacy of immunotherapy?",[236,237,27],"Pain Management","Immune Checkpoint Inhibitor",[239,240,241],"pain management","opioids","immune checkpoint inhibitor","2025-09-16",{"date":244,"type":37},"2025-09-23",{"date":246,"type":20},"2025-09-17",{"date":248,"type":20},"2027-10-01",{"name":250,"class":44},"Hubei Cancer Hospital",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":258,"sex":259,"minAge":54,"maxAge":232,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":45},"100606646","phase-4-erector-spinae-block-in-reducing-peri-operative-opioid-consumption-in-total-abdominal-hystrectomy-100606646","NCT07178262","Erector Spinae Block in Reducing Peri-operative Opioid Consumption in Total Abdominal Hystrectomy","Opioid Sparing Effect of Erector Spinae Block in Patients Undergoing Total Abdominal Hysterectomy; A Randomized Control Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) class: I, II and III .\n* Elective Hysterectomy under General Anesthesia.\n\nExclusion Criteria:\n\n* Lack of consent\n* Body mass index \\>35 kg\u002Fm2\n* Allergic to study medicine\n* Opioid abuse or misuse disorder\n* Chronic pain",true,"FEMALE",{"count":57,"type":20},[262],"PHASE4","Hystrectomy is a surgical procedure that involves removal of uterus from the body of patient using a lower abdominal incision. This is an extremely painful procedure which causes discomfort and greatly increases opioids consumption in the peri-operative period. This can be reduced by using nerve blocks such as Erector spinae plane block.",[265,266,27],"Erector Spinae Block","Enhanced Recovery After Surgery (ERAS) Protocol","2025-09-12",{"date":246,"type":37},{"date":270,"type":37},"2025-08-01",{"date":272,"type":20},"2025-10-30",{"name":274,"class":44},"Kulsoom International Hospital",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":286,"conditions":287,"keywords":293,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":110},"100558236","phase-2-glp-1r-agonist-treatment-for-opioid-use-disorder-100558236","NCT06548490","GLP-1R Agonist Treatment for Opioid Use Disorder","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Body mass index (BMI) \\> 18.\n* Able and willing to provide informed consent prior to any study-related activities.\n* Current diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 Opioid Use Disorder (OUD) as per the Mini International Neuropsychiatric Interview (MINI) or per the site clinic diagnosis. Patients are eligible if they have a MINI \\> 3 (\"moderate\" or \"severe\" in the \"Specify If\" box in the Substance Use Disorder (Non-Alcohol) module for the category of opiates).\n* Currently receiving outpatient treatment for OUD and at least 2 weeks on buprenorphine (BUP) or 4 weeks on methadone at the study site and\u002For at an associated clinic at the time of enrollment.\n* Have at least 1 urine test positive for opioids after 2 weeks on BUP or 4 weeks on methadone.\n* Have positive self-reporting of opioid use after 2 weeks on BUP or 4 weeks on methadone.\n* If anatomically capable of becoming pregnant and of childbearing age, is not pregnant (confirmed) or breastfeeding at the time of enrollment and agrees to use a medically accepted method of birth control or to abstain from sexual intercourse while in the study.\n* Able to read and communicate in English to the level required to accept standard care and complete all study requirements.\n* Able and willing to engage\u002Fadhere to the entirety of the study protocol (19 weeks).\n* Not currently a prisoner.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 75 years.\n* BMI \\\u003C18.\n* Individuals who are pregnant, planning pregnancy, breastfeeding, or unwilling to use adequate contraceptive measures.\n* Current use of glucagon-like peptide 1 receptor (GLP-1R) agonist.\n* History of angioedema, serious hypersensitivity reaction, or anaphylactic reaction to semaglutide or another GLP-1R agonist.\n* Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome Type 2 (MEN 2) or thyroid nodule.\n* Type 1 diabetes or history of diabetic ketoacidosis.\n* Type 2 diabetes mellitus or current use of a dipeptidyl peptidase-4 (DPP-4) inhibitor.\n* Past 30-day use of Sincalide, Sulfonylureas, insulin and insulin products or other medications that may interact with semaglutide.\n* Hypoglycemia on intake visit (blood glucose \\\u003C 60 mg\u002FdL).\n* End-stage renal failure, on dialysis, or glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin per 1.73 square meters or previous renal transplant.\n* End stage liver disease or previous liver transplant.\n* Current or past diagnosis of pancreatitis, gastroparesis, or other severe gastrointestinal (GI) disease.\n* Current or past diagnosis of gallbladder disease or gallstones.\n* Serious cardiovascular disease within the past 6 months (e.g. uncontrolled hypertension, heart failure, significant cardiac arrhythmias, myocardial infarction, presence of angina pectoris, symptomatic coronary artery disease, deep vein thrombosis, pulmonary embolism, second- or third-degree heart block, mitral valve or aortic stenosis, hypertrophic cardiomyopathy, stroke).\n* Severe co-occurring psychiatric disorder (e.g., bipolar disorder, psychotic disorder, schizophrenia), and\u002For history or evidence of organic brain disease or dementia that would compromise safety or compliance with the study protocol in the opinion of the site principal investigator (PI) and\u002For physician. As there is no specific scale that determines this, this will include the Site PI\u002Fphysician determining if the potential participant shows consistency in decision making and if they are alert and oriented to time, date, day and location.\n* Significant risk of suicide requiring a different\u002Fhigher level of care, according to the clinical judgment of the study physician or site principal investigator, or history of suicide attempts within the past 1 year, unless participation is cleared by clinician assessment and\u002For judgment. A Columbia-Suicide Severity Rating Scale (C-SSRS) indicating a history of suicide attempts within the past year, or active suicidal ideation within the past 1 month, will qualify as significant risk of suicide.\n* Treatment with any investigational drug in the one month preceding the study.\n* Any contraindication to both methadone and BUP.\n* Any contraindication to a GLP-1R agonist.\n* Previous randomization for participation in this trial.\n* Any other condition at screening that precludes safe participation in the trial in the judgment of the site PI or study physician.\n* Plans for travel outside of the local area over the 19 weeks (1 week of baseline, 12 weeks of medication, 1 week wash-out, and follow-up after a further 28 days) that would interfere with visits during the study period or other logistic factors that would make it difficult to commit to the entire duration of study.\n* Currently a prisoner.","75 Years",{"count":283,"type":20},200,[285],"PHASE2","The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is:\n\n• Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids?\n\nThe investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids.\n\nThe participants will:\n\n* Take semaglutide or a placebo every week for 12 weeks\n* Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires\n* Complete smartphone surveys sent at set times during the study",[93,288,289,290,291,292,27],"Opioid Abuse and Addiction","Narcotic-Related Disorders","Substance-Related Disorders","Chemically-Induced Disorders","Mental Disorder",[294,295,296,297,298],"Opiate treatment","Opioid treatment","Glucagon-Like Peptide-1 Agonist","Opioid use disorder","Semaglutide","2025-08-11",{"date":301,"type":37},"2025-08-14",{"date":303,"type":37},"2025-01-13",{"date":305,"type":20},"2026-11",{"name":307,"class":44},"Milton S. Hershey Medical Center",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":259,"minAge":315,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":319,"briefSummary":320,"conditions":321,"keywords":324,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":45},"100601726","the-effect-of-opioid-free-anesthesia-using-ultrasound-guided-bilateral-transversus-abdominus-plane-block-and-dexmedetomidine-infusion-100601726","NCT07114237","The Effect of Opioid Free Anesthesia Using Ultrasound-Guided Bilateral Transversus Abdominus Plane Block and Dexmedetomidine Infusion","The Effect of Opioid Free Anesthesia in Morbid Obese Patient Undergoing Gynecological Surgeries Using Ultrasound-Guided Bilateral Transversus Abdominus Plane Block and Dexmedetomidine Infusion: A Randomized Controlled","Inclusion Criteria:\n\n* 50 female patients aged 21-65 years.\n* Patients with a Body mass index≥ 35 kg\u002Fm2\n* American society of Anesthesiology class II-III.\n* Undergoing elective gynecological surgeries.\n\nExclusion Criteria:\n\n* Patient refusal.\n* History of allergy to local anesthetic.\n* Liver or renal pathology affecting drug elimination.\n* Mental dysfunction or cognitive disorders.\n* Patients on chronic pain medications.\n* Hypotension, bradycardia, atrioventricular block, intraventricular or sinoatrial block.\n* Coagulopathy","21 Years","65 Years",{"count":318,"type":20},150,[23],"This study aimed to determine the effects of Opioid-free anesthesia using dexmedetomidine and bilateral Transversus abdominis plane block on the quality of recovery, incidence of Opioid-free anesthesia, and post-operative pain and delirium in morbid obese patients undergoing gynecological surgeries.",[322,27,323],"Anesthesia","Gynecological Surgery",[325,326,327,328],"Gynecological Surgeries","Opioid Free Anesthesia","Morbid Obese","Dexmedetomidine Infusion","2025-08-04",{"date":299,"type":37},{"date":332,"type":20},"2025-08-30",{"date":137,"type":20},{"name":335,"class":44},"Tanta University",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":281,"enrollmentInfo":343,"targetDuration":4,"studyType":21,"phases":345,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":45},"100477999","phase-2-perioperative-analgesia-modes-in-minimally-invasive-esophagectomy-100477999","NCT05504265","Perioperative Analgesia Modes in Minimally Invasive Esophagectomy","Comparison of Efficacy and Safety of Different Analgesic Modes in Minimally Invasive Esophagectomy for Esophageal Cancer","Inclusion Criteria:\n\n* 18-75 years;\n* Patients underwent laparoscopic and thoracoscopic or robotic-assisted minimally invasive esophagectomy ;\n* Informed consent.\n\nExclusion Criteria:\n\n* Has a history of cholecystitis or urolithiasis within 3 months;\n* Has a history of atherothrombosis (peripheral arterial disease), stroke, myocardial infarction;\n* With lung diseases, such as pneumonia, atelectasis, emphysema, pulmonary bullae, etc;\n* Preoperative cardiac function grade ≥ III or coronary artery stenosis;\n* Preoperative indwelling of a thoracic drainage tube;\n* Long-term heavy drinker(heavy drinking was defined as follows: for men, consuming more than 4 drinks on any day or more than 14 drinks per week; For women, consuming more than 3 drinks on any day or more than 7 drinks per week);\n* Opioid-tolerant patients(defined as those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid);\n* With painful skin complications, such as rashes and blisters;\n* Conversion to open surgery;\n* The postoperative ventilation function was limited, or the duration of endotracheal intubation was more than 24h.",{"count":344,"type":20},102,[285,346],"PHASE3","This study was designed to compare analgesic efficacy and safety of different perioperative analgesic modes in minimally invasive esophagectomy for esophageal cancer.",[349,350,351,27,352],"Esophageal Cancer","Perioperative Analgesia","NSAIDs","Patient-controlled Analgesia","2025-03-17",{"date":355,"type":37},"2025-03-20",{"date":357,"type":37},"2022-10-10",{"date":359,"type":20},"2025-12-20",{"name":361,"class":44},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":372,"briefSummary":373,"conditions":374,"keywords":377,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":45},"100555013","phase-4-low-dose-ketamine-infusion-during-burn-wound-care-100555013","NCT06506565","Low-Dose Ketamine Infusion During Burn Wound Care","A Randomized, Placebo-Controlled, Double-Blind Evaluation of Low-Dose Ketamine Infusion During Burn Wound Care Procedures to Improve Pain Intensity and Reduce Opioid Consumption","IMPROVE","Inclusion Criteria:\n\n* Admitted to burn service with thermal injury\n\nExclusion Criteria:\n\n* unable\u002Funwilling to consent within 72 hours\n* unable to report NRS\n* known contraindication to ketamine\n* \\\u003C than 18 years of age\n* pregnant\n* incarcerated\n* TBSA over 50 %",{"count":371,"type":20},140,[262],"The current standard of care (SOC) (i.e. fentanyl and midazolam) offers limited efficacy for preventing or relieving pain. Ketamine infusions may provide the benefits of analgesia, minimize adverse events, and reduce opioid use. The purpose of this study is to determine if adding a low dose ketamine infusion during wound care will safely provide pain relief for patients with burn injury.",[375,28,376,27],"Burn","Dissociation",[378,379,128,380],"ketamine","burn","analgesia","2024-12-09",{"date":383,"type":37},"2024-12-13",{"date":385,"type":37},"2024-07-08",{"date":387,"type":20},"2025-12",{"name":389,"class":44},"University of Tennessee"]